BGS-649

ReproNovo has raised $65 million in Series A financing led by Jeito Capital to advance two Phase 2-ready compounds targeting male infertility, adenomyosis, and embryo implantation success.

Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.

Mereo BioPharma's setrusumab Phase 3 Orbit study for osteogenesis imperfecta is ongoing, with a second interim analysis expected in mid-2025.

The FDA granted Breakthrough Therapy Designation to setrusumab for reducing fracture risk in osteogenesis imperfecta (OI) types I, III, and IV, for patients aged 2 years and older.

Mereo BioPharma's partner, Ultragenyx, anticipates completing enrollment for the Phase 3 Orbit study of setrusumab in Osteogenesis Imperfecta (OI) by the end of Q1 2024.